| 周雨晨,张爱琴,陈卓,许天愉.清肺合剂干预肺癌患者病毒感染肺系症状的临床研究[J].浙江中西医结合杂志,2026,36(3): |
| 清肺合剂干预肺癌患者病毒感染肺系症状的临床研究 |
| Clinical study on the intervention of Qingfei mixtures in lung cancer patients with symptoms of viral infection of the pulmonary system |
| 投稿时间：2025-05-23 修订日期：2026-01-14 |
| DOI： |
| 中文关键词: 清肺合剂 肺癌 病毒感染 咳嗽 肺纤维化 |
| 英文关键词:Qinglong Combination lung cancer viral infection cough pulmonary fibrosis |
| 基金项目:国家中医药管理局科技司-浙江省中医药管理局共建科技计划项目(No.GZY-ZJ-KJ-24007) |
|
| 摘要点击次数: 70 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：初步探讨清肺合剂干预肺癌患者病毒感染肺系症状的临床疗效。方法：选取2024年11月至2025年5月在浙江省肿瘤医院234例病原体检测阳性的肺恶性肿瘤患者，根据治疗方案不同分为观察组（176例，常规治疗+清肺合剂）和对照组（58例，常规治疗）。分别在治疗2周、4周后评估患者咳嗽（CET）气急（mMRC）症状改善情况、体能情况（ECOG）、血清肿瘤标志物（CEA、CY21-1、NSE、SCC）、肺纤维化程度（Camiciottoli）。结果：治疗后，观察组CET评分（9.04±2.83 vs 10.76±2.72,P＜0.01）和ECOG评分（1.18±0.59 vs 1.45±0.63,P＜0.01）显著优于对照组；而mMRC评分呈现下降趋势（1.11±0.89 vs 1.34±0.81），但组间差异未达到统计学意义(P=0.098)。肿瘤标志物分析显示，在腺癌患者中，观察组CEA水平保持稳定（P=0.366），而对照组显著升高（6.74 vs 4.19，P=0.037）；在鳞癌患者中，观察组SCC水平显著降低（1.02 vs 0.80，P=0.039），对照组则呈现升高趋势（1.30 vs 1.50，P=0.046）。肺纤维化评分方面，观察组Camiciottoli视觉评分显著降低（10.20±5.41 vs 10.69±5.05,P=0.001），而对照组略有上升（12.14±4.83 vs 12.09±12.14,P=0.425），组间差异显著（P=0.005）。结论：清肺合剂可有效缓解肺癌患者病毒感染肺系症状，改善肺纤维化水平，延缓抗肿瘤治疗导致的体能下降，其治疗效应可能与CEA、SCC的水平变化存在关联。 |
| 英文摘要: |
| Abstract: Objective: To preliminarily investigate the clinical efficacy of Qingfei Mixtures in managing pulmonary symptoms induced by viral infection in lung cancer patients. Methods: A total of 234 lung cancer patients with positive pathogen tests were selected from Zhejiang Cancer Hospital between November 2024 and May 2025, and divided into an observation group (176 cases, conventional treatment + Qingfei Mixture) and a control group (58 cases, conventional treatment) based on different treatment regimens. Patients were evaluated at 2 and 4 weeks after treatment for improvement in cough (CET) and dyspnea (mMRC) symptoms, performance status (ECOG), serum tumor markers (CEA, CY21-1, NSE, SCC), and degree of pulmonary fibrosis (Camiciottoli). Results: After treatment, the observation group showed significantly better CET scores (9.04±2.83 vs 10.76±2.72, P<0.01) and ECOG scores (1.18±0.59 vs 1.45±0.63, P<0.01) compared to the control group; while mMRC scores showed a decreasing trend (1.11±0.89 vs 1.34±0.81), the intergroup difference did not reach statistical significance (P=0.098). Tumor marker analysis revealed that in adenocarcinoma patients, CEA levels remained stable in the observation group (P=0.366) while significantly increasing in the control group (6.74 vs 4.19, P=0.037); in squamous cell carcinoma patients, SCC levels remained stable in the observation group (1.02 vs 0.80, P=0.039) while showing an increasing trend in the control group (1.30 vs 1.50, P=0.046). Regarding pulmonary fibrosis scores, the observation group showed significant reduction in Camiciottoli visual scores (10.20±5.41 vs 10.69±5.05, P=0.001), while the control group showed slight increase (12.14±4.83 vs 12.09±12.14, P=0.425), with significant intergroup difference (P=0.005). Conclusion: Qingfei Mixtures can effectively alleviate pulmonary symptoms induced by viral infection in lung cancer patients, improve pulmonary fibrosis, and delay performance status decline caused by antitumor therapy, with its therapeutic effects potentially associated with changes in CEA and SCC levels. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
